Her2 cross talk and therapeutic resistance in breast cancer

The HER2 receptor tyrosine kinase is amplified and/or overexpressed in approximately 30 percent of metastatic breast cancers. Interactions and cross signaling from the HER2 receptor to other growth factor receptors may potentially contribute to therapeutic resistance. In this review, we discuss HER2...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Frontiers in bioscience Ročník 13; s. 3906
Hlavní autori: Bender, Laura M, Nahta, Rita
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States 01.05.2008
Predmet:
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Antineoplastic Agents - therapeutic use
Antineoplastic Agents, Hormonal - therapeutic use
Breast Neoplasms - drug therapy
Breast Neoplasms - physiopathology
Cell Line, Tumor
Drug Resistance, Neoplasm
Female
Humans
Phosphatidylinositol 3-Kinases - physiology
Receptor Cross-Talk - physiology
Receptor, ErbB-2 - antagonists & inhibitors
Receptor, ErbB-2 - physiology
Receptor, IGF Type 1 - physiology
Receptors, Estrogen - physiology
Signal Transduction
Tamoxifen - therapeutic use
Trastuzumab
ISSN:1093-9946
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:The HER2 receptor tyrosine kinase is amplified and/or overexpressed in approximately 30 percent of metastatic breast cancers. Interactions and cross signaling from the HER2 receptor to other growth factor receptors may potentially contribute to therapeutic resistance. In this review, we discuss HER2 receptor cross talk with the estrogen receptor and implications toward resistance to endocrine therapies. We also review mechanisms of resistance to the HER2-targeted antibody trastuzumab, including signaling from other members of the HER family, increased signaling through the PI3-kinase pathway, and cross talk from the insulin-like growth factor-I receptor to HER2. Finally, we will provide perspective on how HER2 receptor cross talk may provide critical information for developing novel therapeutic options for HER2-overexpressing breast cancers.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1093-9946
DOI:10.2741/2978